-
公开(公告)号:US20100222318A1
公开(公告)日:2010-09-02
申请号:US12642447
申请日:2009-12-18
申请人: Jean Damien Charrier , Steven Durrant , David Kay , Ronald Knegtel , Somhairle MacCormick , Michael Mortimore , Michael O'Donnell , Joanne Pinder , Alistair Rutherford , Anisa Nizarali Virani , Stephen Young , Philip Michael Reaper
发明人: Jean Damien Charrier , Steven Durrant , David Kay , Ronald Knegtel , Somhairle MacCormick , Michael Mortimore , Michael O'Donnell , Joanne Pinder , Alistair Rutherford , Anisa Nizarali Virani , Stephen Young , Philip Michael Reaper
IPC分类号: A61K31/497 , C12N5/02 , C07D413/14 , C07D413/04 , A61K31/5513 , C07D417/04 , A61K31/5377 , A61K31/553 , C07D403/10 , A61K35/04
CPC分类号: C07D413/14 , A61P35/00 , C07D241/28 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/12 , C07D417/14 , C07D471/04
摘要: The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.
摘要翻译: 本发明涉及可用作ATR蛋白激酶抑制剂的吡嗪化合物。 本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病,病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法,如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。 本发明的化合物具有式I:其中变量如本文所定义。